Jeffrey S. Heier, MD

Subretinal therapy offers promise of lighter treatment burden for AMDRGX-314 gene therapy offers patients the potential for a lower treatment burden with one subretinal injection of a gene therapy delivering an anti-vascular endothelial growth factor protein.
Surgical gene therapy study for wet AMD yields mixed resultsIn a phase IIa study of patients with neovascular age-related macular degeneration, a single subretinal injection of rAAV.sFlt-1 gene therapy demonstrated acceptable safety, but not a complete or durable anti-VEGF response. Additional preclinical research is under way.
Ohr completes wet-AMD trial enrollmentOhr Pharmaceuticals has completed the enrollment of its OHR-022 phase II clinical trial evaluating its treatment of we age-related macular degeneration (AMD), Squalamine eye drops.